Position
Fidelity in Theravance Biopharma, Inc.
Back to the book · All holders of TBPH
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $94.7K$16.23 → $17.00
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 5.42K | $101.4K | — | — | — | 0.0% |
| Q1 2026 | 123K | $2M | $16.23 | −$13.4K | $1.91M | 0.0% |
| Q2 2026 | 133.9K | $2.28M | $17.00 | $94.7K | $185.3K | 0.0% |